BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Vididencel readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Vididencel\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07651878-2981@assetmemo.bio
DTSTAMP:20261121T005722Z
DTSTART;VALUE=DATE:20290901
DTEND;VALUE=DATE:20290902
SUMMARY:Vididencel: Phase 1 readout est. (NCT07651878)
DESCRIPTION:Vididencel\, phase 1\, Chronic Myeloid Leukemia.\nStudy: Vidide
 ncel in CML-CP Patients With MRD\nEstimated primary completion: 1 Septembe
 r 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/vididencel#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076518
 78
URL:https://assetmemo.bio/drug/vididencel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
